Financial Data and Key Metrics Changes - In Q4 2025, net sales decreased by 2.4% to $1.52 billion, with comparable sales down 1.6% [9][10] - For the full year 2025, Adjusted EBITDA increased by 21.3% to $408 million, with a margin of 6.8% [8][9] - Operating cash flow rose by 77% year-over-year, contributing to a reduction in the leverage ratio from 4.2x to 3x [4][9] - Free cash flow improved by 276% to $187 million [9][12] Business Line Data and Key Metrics Changes - The company focused on moving away from unprofitable sales, resulting in a decline in total sales but improved profitability [10][12] - Gross margin rate expanded by 66 basis points to 38.7% for the full year 2025 [8] - Operating profit increased by $113 million, with operating margin expanding by 190 basis points [8] Market Data and Key Metrics Changes - The company ended 2025 with 1,382 stores in the U.S., following 25 net store closures in 2024 and 16 in 2025 [10] - The company expects net store closures between 15 and 20 in 2026, with closures weighted towards the latter half of the year [15] Company Strategy and Development Direction - The company is entering a new phase called "Reach for the Sky," focusing on sustainable top-line growth through four pillars: compelling product offerings, services at scale, trusted store experiences, and an integrated omni-channel model [18][19] - The strategy includes expanding the fresh food category, launching new national brands, and increasing the frequency of product drops [20][21][23] - The company aims to leverage its wholly owned services, including vet hospitals and grooming, as a key growth engine [26][27] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in starting 2026 from a position of strength despite a challenging macro environment [14] - The guidance for Q1 2026 anticipates net sales to be down 1% to flat, with Adjusted EBITDA expected between $92 million and $94 million [15][16] - Management emphasized that growth initiatives are designed to be self-help in nature, not reliant on favorable macro conditions [34] Other Important Information - The company has made significant progress in improving its economic model, focusing on profitability and cash generation [8][12] - The company plans to enhance its loyalty program and digital capabilities in 2026 [31][32] Q&A Session Questions and Answers Question: What will lead Petco's growth from here? - Management indicated that growth will come from all four pillars simultaneously, with product taking the longest to implement [37][39] Question: What are the drivers of the increase in gross margins? - Management highlighted the focus on pricing, promotions, and product mix as key levers for maintaining healthy margins [44][45] Question: How is the brand assortment evolving? - Management stated that the brand assortment is widening to cater to both premium and mainstream customers [52][54] Question: What percentage of customers engage in services? - Management noted that there is significant room for growth in services, particularly in vet hospitals and grooming [61][63] Question: How will the company capture customers who do not buy dog food? - Management emphasized the importance of cross-selling and leveraging customer data to increase sales among existing customers [66][67]

Financial Data and Key Metrics Changes - For the third fiscal quarter, the company reported revenue of $16.9 million, which is down from $18.9 million for the same period in the prior fiscal year and essentially the same as the second fiscal quarter of this fiscal year [13][19] - The revenue from commercial and U.S. government satellite programs was approximately $4.2 million, accounting for 25% of total revenue, compared to $11.2 million or 59% in the same period of the prior fiscal year [14] - Revenues from non-space U.S. government and Department of Defense customers were $12.5 million, representing 74% of consolidated revenue, up from 39% in the prior fiscal year [15] - Consolidated net income for the three months ended January 31, 2026, was approximately $1.6 million or $0.16 per share, compared to approximately $15.4 million or $1.60 per share for the same period of the previous fiscal year [20] Business Line Data and Key Metrics Changes - Revenue from satellite payload contracts was recognized primarily under the percentage of completion method and reported only in the FEI New York segment [15] - The company experienced a decrease in gross margin and gross margin rate due to a change in the mix of high-margin production satellite programs in the prior year versus lower-margin programs in the current period [16] - Selling, General, and Administrative (SG&A) expenses increased to approximately 21% of consolidated revenue, up from 18% in the prior year [17] Market Data and Key Metrics Changes - The company’s fully funded backlog at the end of January 2026 was approximately $83 million, a new all-time high, compared to approximately $70 million for the previous fiscal year [21] - The company anticipates that the new contracts announced will start to enter backlog in the current fiscal fourth quarter, contributing to the growth towards the $100 million backlog target [7][69] Company Strategy and Development Direction - The company is focusing on growth in large and growing end markets, including quantum sensing and proliferated satellites, alongside ongoing strength in space and defense businesses [3][4] - The management emphasized the importance of maintaining a balance between traditional and new business lines, expecting both to grow simultaneously [5] - The company is investing in R&D to keep its products at the state of the art, with plans to continue this investment in the future [18] Management's Comments on Operating Environment and Future Outlook - The management acknowledged the current geopolitical climate, including the ongoing war, which has increased reliance on traditional defense technologies [9][11] - There is an expectation for strong opportunities in both traditional defense and next-generation modalities, particularly in alternative positioning, navigation, and timing systems [11][12] - The management expressed optimism about the future growth of the TURbO program, indicating significant revenue potential [34][35] Other Important Information - The company is debt-free and believes its liquidity is adequate to meet operating and investing needs for the next 12 months [23] - The company has already collected over $11 million of cash since February 1, 2026, which is expected to continue building through the quarter [22] Q&A Session Summary Question: Insights on proliferated constellation deals - The management noted success in winning contracts where they can provide a technical edge, but emphasized challenges in low-cost environments [26][27] Question: Details on the $45 million contracts - The management indicated both contracts are significant but did not disclose specific proportions [28][29] Question: Cost structure and operating expenses - The management explained that investments in Colorado are a significant part of current operating expenses, which should normalize over time [31][32] Question: Updates on the TURbO program - The management expressed increased optimism about TURbO, expecting significant revenue growth in the near future [34][35] Question: Clarification on proliferated satellites - The management described proliferated satellites as systems with many more satellites, typically in low Earth orbit, designed to be less costly and more rapidly produced [40][42] Question: Addressing GPS jamming and alternative navigation - The management discussed ongoing projects in magnetic navigation and other non-satellite alternatives to GPS, indicating government interest and funding for these technologies [88][90]

Financial Data and Key Metrics Changes - For the full year 2025, net operating income increased by more than 22% and adjusted EBITDA per share improved by 28% [8][18] - The company realized a 5.9% increase in revenue per occupied room (RevPOR) for Q4 compared to the same quarter in the prior year, with an annual growth of 8.8% [18][19] - Total portfolio NOI at share grew by 22% or $15 million on an annualized basis [21] Business Line Data and Key Metrics Changes - The same-store portfolio saw an additional 20 basis points of sequential occupancy gains in Q4, following a 90 basis point increase in Q3 [18] - The acquisition portfolio experienced a 680 basis point occupancy jump from 2024, with community NOI margin expanding by 550 basis points to 24.7% [19][21] - The 19 communities acquired in 2024 showed a sequential occupancy improvement of 290 basis points from Q3 to Q4, with total occupancy improving by 820 basis points year-over-year [9] Market Data and Key Metrics Changes - The company anticipates accelerated occupancy gains as the 19 communities from the 2024 acquisition cohort move into the same-store portfolio in 2026 [19] - The average annual rent renewal rate on in-place leases for the recent March 1 renewal was 7.9%, applicable to 96% of total same-store residents, up from 6.8% the previous year [25] Company Strategy and Development Direction - The company completed the acquisition of CNL Healthcare Properties for a total consideration of $1.8 billion, enhancing competitive positioning and growth profile [5][6] - Plans are in place to prune approximately 10% of the portfolio based on community count, focusing on recycling capital into higher growth, newer vintage assets [22][39] - The company aims to maintain a focus on delivering excellent clinical care and services while developing a labor model that rewards strong employees [10][16] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the merger's potential to drive improved performance trends and significant upside [10] - The company is targeting growth in revenue per occupied room at or above the same-store growth achieved in 2025 for the full year 2026 [8] - Management highlighted the importance of retaining and developing talent, with a focus on reducing employee turnover [16] Other Important Information - The company has committed to a new upsized $405 million revolver to increase available capital for investment opportunities [14] - The acquisition is expected to provide significant capital for reinvestment in both internal ROI projects and new acquisitions [13] Q&A Session Summary Question: Can you discuss the adjusted EBITDA and interest costs assumptions post-merger? - Management indicated that details will be provided in Q1, aiming for comparability with large-scale REIT reporters [37] Question: What is the timeline for pruning the 10% of the portfolio? - Management expects to make progress within a six to twelve-month timeline, with proceeds primarily used for deleveraging and reinvestment in higher quality assets [39] Question: Is the 16%-17% same-store NOI growth a good run rate number? - Management views this as a starting point for the new asset bucket, with further insights to be provided as normalized FFO metrics are released [40][41] Question: Is the 7.9% rate increase for the legacy pool or the current pool? - The rate increase is for the legacy pool that was implemented recently [46] Question: Will net lease assets be part of the dispositions this year? - Management stated there are no immediate plans to sell net lease assets but will evaluate market conditions for potential opportunities [49]

Financial Data and Key Metrics Changes - Total revenues for Q4 2025 were $38.9 million, up from $21.5 million in Q4 2024, primarily due to a technology transfer agreement with Merck [21] - For the full year 2025, revenue was $70.4 million compared to $59.3 million in 2024 [21] - Product gross margin for Q4 2025 was 64%, consistent with the full year 2025 gross margin, which also stood at 64%, up from 56% in the prior year [22] - Net income for Q4 2025 was $9.6 million, compared to a net loss of $10.4 million in Q4 2024; net loss for the full year 2025 was $44 million, improved from a loss of $65.3 million in 2024 [24][25] Business Line Data and Key Metrics Changes - The small molecule biocatalysis business returned to a healthy profit margin, with stabilization in revenue, supported by a robust pipeline of drugs in late-stage clinical studies [10] - The ECO Synthesis platform achieved significant milestones, including synthesizing 10 grams of commercially relevant siRNA and scaling production to 100 grams, with plans to reach half a kilo by the end of 2026 [6][7] Market Data and Key Metrics Changes - The total addressable annual market for production technologies in five years is estimated to be $2 billion, with a growing demand for siRNA medicines at a rate of 5%-10% per year [5] - The industry is projected to require 10-30 metric tons of oligonucleotide material by 2030, indicating a significant addressable market for the company [57] Company Strategy and Development Direction - The company is focused on establishing itself as a key technology provider in the RNA medicine market through its ECO Synthesis platform, which aims to address challenges in siRNA production [4][5] - Plans include scaling up production capabilities, achieving GMP certification, and expanding partnerships with CDMOs to enhance manufacturing processes [8][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth potential of the ECO Synthesis platform and the overall siRNA market, highlighting the importance of innovation and customer collaboration [12][28] - The company aims to demonstrate proof of success through new contracts and licensing deals in 2026, while maintaining a focus on financial performance and expense management [27][29] Other Important Information - The company ended 2025 with $78.2 million in cash equivalents, expected to fund operations and capital expenditures through the end of 2027 [25] - A restructuring charge of $3.4 million was recorded in Q4 2025 as part of efforts to reduce operating costs and improve gross margins [24] Q&A Session Summary Question: Potential value of stereoisomer control - Management is actively exploring the biological activity of stereo configurations and plans to present data at the TIDES USA meeting, with several customers interested in collaboration [31][32] Question: Understanding the recent deal process - The recent deal involved a small organization with a cardiovascular asset, highlighting the long-term discussions and mutual excitement about the ECO Synthesis platform's capabilities [35][39] Question: Details on the 50-gram contract - The initial agreement is for preclinical work, with expectations that successful data will lead to IND submissions and larger contracts for clinical trials [41][43] Question: Revenue guidance visibility - Management indicated a significant portion of the $72 million-$76 million revenue guidance is based on historical buying practices, though some estimates remain speculative at the beginning of the year [50][51] Question: Growth expectations for biocatalysis business - The small molecule biocatalysis business is expected to stabilize and continue to fuel growth, while higher growth rates are anticipated from the ECO side of the business [62][65]

Financial Data and Key Metrics Changes - In Q4 2025, net sales decreased by 2.4% to $1.52 billion, with comparable sales down 1.6% [9][10] - For the full year 2025, Adjusted EBITDA increased by 21.3% to $408 million, with a margin of 6.8% [8][9] - Operating cash flow rose by 77% year-over-year, contributing to a reduction in the leverage ratio from 4.2x to 3x [4][9] - Free cash flow improved by 276% to $187 million [9][12] Business Line Data and Key Metrics Changes - The company focused on moving away from unprofitable sales, resulting in a decline in total sales but improved profitability [10][12] - Gross margin rate expanded by 66 basis points to 38.7% for the full year 2025 [8] - Operating profit increased by $113 million, with an operating margin expansion of 190 basis points [8] Market Data and Key Metrics Changes - The company ended 2025 with 1,382 stores in the U.S., following 25 net store closures in 2024 and 16 in 2025 [10] - The company expects net store closures between 15 and 20 in 2026, with closures weighted towards the latter half of the year [15][16] Company Strategy and Development Direction - The company is entering a new phase called "Reach for the Sky," focusing on sustainable top-line growth through four pillars: compelling product offerings, services at scale, trusted store experiences, and an integrated omni-channel model [18][19] - The strategy includes expanding the fresh food category, launching new national brands, and increasing the frequency of product drops [20][21][24] - The company aims to leverage its wholly owned vet services as a key growth engine, with plans to optimize existing locations and expand in 2027 [26][27] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in starting 2026 from a position of strength despite a challenging macro environment [14] - The guidance for Q1 2026 anticipates net sales to be down 1% to flat, with Adjusted EBITDA expected between $92 million and $94 million [15][16] - Management emphasized that growth initiatives are designed to be self-help in nature, not reliant on favorable macro conditions [34] Other Important Information - The company has made significant progress in improving its economic model, focusing on profitability and cash generation [8][12] - The management team has undergone changes, with new leadership contributing to a transformative year [5][6] Q&A Session Summary Question: What will lead Petco's growth from here? - Management indicated that growth will come from all four pillars simultaneously, with product development taking the longest to implement [37][39] Question: What are the drivers of the increase in gross margins? - Management highlighted the focus on pricing, promotions, and product mix as key levers for maintaining healthy gross margins [44][45] Question: How is the brand assortment evolving? - Management stated that the brand strategy is widening to cater to both premium and mainstream customers, ensuring a diverse product offering [52][54] Question: What percentage of customers engage in services? - Management noted that there is significant room for growth in services, particularly in veterinary services, which are currently available in about 20% of stores [61][63] Question: How will the company capture customers who do not currently buy dog food? - Management emphasized the importance of cross-selling and leveraging customer data to increase sales among existing customers [66][67]

Financial Data and Key Metrics Changes - The company finished fiscal 2025 with total net sales of $155.1 million, an increase of 5.3% despite having 17 fewer stores than the previous year [11] - Comparable net sales for the fourth quarter increased by 10.1%, with physical stores and e-commerce contributing increases of 10.3% and 9.8% respectively [11] - Gross margin improved to 33.2% of net sales, an increase of 720 basis points compared to 26% last year [12] - Net income improved to $2.9 million or $0.10 per diluted share, compared to a net loss of $13.7 million or $0.45 per share last year [16] Business Line Data and Key Metrics Changes - Total net sales from physical stores increased by 3.6% despite a 7.1% reduction in store count, representing 72.3% of total net sales [12] - E-commerce net sales represented 27.7% of total net sales, up from 26.5% last year [12] - Product margins improved by 470 basis points due to higher initial markups and lower markdowns associated with reduced inventory [13] Market Data and Key Metrics Changes - The company experienced six consecutive months of positive comparable sales momentum, with 18 consecutive positive comp weeks [4] - February 2026 saw a comparable net sales increase of 20.1% compared to the same period in 2025 [17] Company Strategy and Development Direction - The company plans to open four to six new stores in fiscal 2026, shifting from a store closure strategy to a disciplined approach to growth [7] - Infrastructure investments and a price optimization tool have contributed to improved product margins and operational efficiencies [8] - The company is optimistic about its prospects for fiscal 2026, believing that the turnaround is real and fundamentals are fixed [9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ability to sustain growth, although they acknowledged that macroeconomic conditions could impact discretionary retail spending [28] - The company expects further improvement in both top line and bottom line performance in each quarter of fiscal 2026 [10] - Management indicated that an annualized comparable net sales increase of approximately 8%-9% would be necessary to begin generating profitability for fiscal 2026 [19] Other Important Information - The company ended fiscal 2025 with total liquidity of $87.8 million, including cash of $46.3 million and no debt [16] - Total capital expenditures for fiscal 2025 were $4.7 million, down from $8.2 million in fiscal 2024 [16] Q&A Session Summary Question: Composition of strong comp for the fourth quarter - Management noted significant acceleration in comp sales from month to month, with strong performance across all departments and improved traffic [23] Question: What is driving higher traffic? - Management indicated strength across all categories, improved inventory levels, and effective marketing strategies as key drivers of higher traffic [25][26] Question: Path forward on store expansion - Management expressed confidence in unit economics and the ability to execute, while remaining cautious about the consumer spending environment [28] Question: CapEx for store expansion - Management expects CapEx to be in the range of $8 million-$9 million, with a focus on improving sales per square foot [29][43] Question: Assumptions for profitability outlook - Management clarified that an 8%-9% comp increase does not correlate to a proportionate increase in SG&A, and they expect to continue improving product margins [48]

Financial Data and Key Metrics Changes - For Q4 2025, the company reported revenue of $397.6 million, a 17% year-over-year increase, with organic growth of 12% [15] - Adjusted EBITDA grew 53% year-over-year to $39.5 million, with margins expanding to 9.9% [18] - Full-year adjusted EBITDA for 2025 was $115 million, exceeding guidance [20] Business Line Data and Key Metrics Changes - The company served over 205,000 residents, a 10% increase year-over-year, with script volume growing 14% [15] - Vaccine script volumes increased by 3% year-over-year, contributing to improved profitability due to better purchasing and reimbursement [16] - Adjusted SG&A was 13% of revenue, down from 13.7% in the previous year, reflecting increased scale efficiencies [17] Market Data and Key Metrics Changes - The company anticipates continued pressure in the long-term care pharmacy ecosystem due to the IRA, but believes its scale and local service model will provide stability [10] - The demographic shift, with the first cohort of the "silver tsunami" entering their 80s, is expected to create a tailwind for the company [10] Company Strategy and Development Direction - The company plans to continue investing in acquisitions and greenfield startups while enhancing data analytics capabilities [6] - The focus remains on supporting partners with consistent, reliable execution amid industry changes [11] - The company is raising its 2026 adjusted EBITDA guidance to $120 million-$124 million, reflecting confidence in continued growth momentum [13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in offsetting anticipated EBITDA impacts from the IRA in 2026 [9] - The company is closely monitoring operational complexities introduced by the IRA and aims to avoid disruptions to service levels and cash flow [10] - Management highlighted the importance of maintaining service continuity amid industry consolidation and operational changes [48] Other Important Information - The company increased its cash balance by approximately $60 million, reflecting strong cash generation [6] - Full-year return on equity was 27%, underscoring a disciplined approach to capital allocation [7] Q&A Session Summary Question: Can you help us understand what's durable, what's vaccine, and what's non-recurring in the quarter? - Management indicated that the run rate for adjusted EBITDA is approximately $110 million, with certain positive variabilities not projected to continue [25] Question: Did the vaccine program contribute more this year than last year? - Management confirmed that the vaccine program continued to be significant in Q4, with improved reimbursement contributing to profitability [27] Question: What were you able to get done from a contracting standpoint to better balance profit streams? - Management noted progress in aligning gross margin dollars with the high percentage of generic prescriptions dispensed [29] Question: Is the gap between potential margin and realized margin still what it was a couple of quarters ago? - Management reported that the gap has increased to approximately 90 basis points, reflecting ongoing investments for future profitability [30] Question: Can you discuss the opportunity around share gain with struggling competitors? - Management acknowledged potential opportunities arising from industry disruptions, including bankruptcy filings among competitors [41] Question: Are you seeing efficiencies and improvements in labor inflation? - Management indicated that efficiencies are primarily driven by scaling the existing labor force rather than improvements in labor inflation [42] Question: How do you ensure continuity of service amid operational changes? - Management emphasized that industry consolidation provides opportunities to maintain service and meet new operating groups [48]

Financial Data and Key Metrics Changes - In Q4 2025, CI&T reported record revenue of $134.3 million, reflecting a 19.3% organic growth compared to Q4 2024, and a 13.9% growth on a constant currency basis [6][24] - For the full year 2025, total revenue reached $489.7 million, marking an 11.5% increase over 2024, or 13.2% on a constant currency basis [24] - Adjusted EBITDA margin for Q4 was 18.4%, with adjusted profit margin at 14% [7][27] - Full year adjusted EBITDA was BRL 89.4 million, up 9.1% from 2024, resulting in a full year margin of 18.3% [27][29] Business Line Data and Key Metrics Changes - CI&T's AI-powered offerings have expanded the pipeline and increased engagement quality, leading to a 10x productivity increase in some client cases [8][20] - The company has embedded AI into core offerings, entering an acceleration phase that enhances value delivery [8][24] Market Data and Key Metrics Changes - Latin America experienced a remarkable 26.8% revenue growth for the full year, driven by digital and AI modernization [25] - North America maintained a steady growth trajectory with a 9.2% year-over-year revenue increase [25] Company Strategy and Development Direction - CI&T is focused on transforming its operating model to scale AI across enterprises, emphasizing the importance of aligning people, processes, and technology [5][6] - The company is transitioning to modern engagement models, moving from time and materials to fixed price, outcome-based, and consumption-based contracts [18][80] - CI&T aims to redefine the unit economics of software production, capturing significant performance arbitrage through AI-augmented solutions [17][18] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in sustaining growth while investing in an AI-native operating model, projecting Q1 2026 revenue of at least $134.7 million, representing 21.5% year-over-year growth [31] - The company anticipates a favorable FX tailwind of approximately 300 basis points for 2026 [31] Other Important Information - CI&T was recognized as a leader in enterprise data modernization and AI services by ISG, and earned the AWS Generative AI Services Competency seal [22][21] - The company has a strong pipeline, with a 30% increase compared to the same period last year, driven by AI demand [36] Q&A Session Summary Question: Guidance and Assumptions for Q1 - Management indicated a strong exit rate for Q4 and a solid commercial pipeline, with macro uncertainty reflected in the lower end of guidance [35] Question: Impact of Geopolitical Uncertainty - No significant impacts from geopolitical uncertainty were observed in Q1 [37] Question: Performance of Top Clients - Revenue from top 10 clients grew 16.5% year-over-year, with strong expansion across all cohorts [42] Question: AI and Agentic Activity Mix - Demand is categorized into foundational spending for legacy modernization and direct AI investments for hyper-efficiency [49] Question: Adjusted EBITDA Margin Drivers - Investments in workforce and AI platforms contributed to margin fluctuations, with expectations for gradual recovery as productivity tools are rolled out [51] Question: Alternative Billing Models - CI&T is experimenting with various billing models, including outcome-based contracts, which could enhance margins over time [80]

Financial Data and Key Metrics Changes - The company finished fiscal 2025 with total net sales of $155.1 million, an increase of 5.3% despite having 17 fewer stores than the previous year [11] - Comparable net sales for the fourth quarter increased by 10.1%, with physical stores and e-commerce contributing increases of 10.3% and 9.8% respectively [11] - Gross margin improved to 33.2% of net sales, an increase of 720 basis points compared to 26% last year [12] - Net income improved to $2.9 million or $0.10 per diluted share, compared to a net loss of $13.7 million or $0.45 per share last year [16] Business Line Data and Key Metrics Changes - Total net sales from physical stores increased by 3.6% despite a 7.1% reduction in store count, representing 72.3% of total net sales [12] - E-commerce net sales represented 27.7% of total net sales, up from 26.5% last year [12] - Product margins improved by 470 basis points due to higher initial markups and lower markdowns associated with reduced inventory [13] Market Data and Key Metrics Changes - The company experienced 6 consecutive months of positive comparable sales momentum, with 18 consecutive positive comp weeks leading into fiscal 2026 [4] - February 2026 saw a +20% comparable net sales result, indicating strong early momentum for fiscal 2026 [4] Company Strategy and Development Direction - The company is shifting from a store closure strategy to a disciplined approach to new store openings, planning to open 4-6 new stores in fiscal 2026 [7] - Significant investments in infrastructure and technology, including an AI-driven merchandise allocation tool, are expected to enhance operational efficiencies [8] - The company aims to continue building on the progress made in fiscal 2025, focusing on optimizing operations and improving customer engagement through enhanced marketing strategies [6][9] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's turnaround, noting that fundamentals are fixed and top-line growth is expected to continue [9] - The company is not yet profitable on an annualized basis but sees a clear path to profitability after generating profit in two of the last three quarters [9] - Management highlighted the importance of consumer spending environment for future growth, indicating that macroeconomic conditions could impact discretionary retail spending [28] Other Important Information - The company ended fiscal 2025 with total liquidity of $87.8 million, including cash of $46.3 million and no debt [16] - Total capital expenditures for fiscal 2025 were $4.7 million, down from $8.2 million in fiscal 2024 [16] Q&A Session Summary Question: Composition of strong comp for the fourth quarter - Management noted significant acceleration in comp sales from +1% in August to +20.1% in February, with strong traffic and conversion rates across all departments [23] Question: What is driving higher traffic? - Management indicated strength across all categories, improved inventory health, and effective marketing strategies as key drivers of higher traffic [25][26] Question: Path forward on store expansion - Management expressed confidence in unit economics and plans to be more aggressive in store expansion in 2027, depending on consumer spending environment [28] Question: CapEx for store expansion - CapEx is expected to be in the range of $8-$9 million, with a focus on improving sales per square foot and regaining lost productivity [29][43] Question: Assumptions for profitability outlook - Management clarified that an 8%-9% comp increase does not correlate to a proportionate increase in SG&A, with ongoing efficiency improvements expected [48]

Financial Data and Key Metrics Changes - Total revenues for Q4 2025 were $38.9 million, up from $21.5 million in Q4 2024, primarily due to a technology transfer agreement with Merck [20] - For the full year 2025, revenue was $70.4 million compared to $59.3 million in 2024 [20] - Product gross margin for Q4 2025 was 64%, consistent with the full year 2025 gross margin, which also stood at 64%, an increase from 56% in the prior year [20][21] - Net income for Q4 2025 was $9.6 million, compared to a loss of $10.4 million in Q4 2024, while the net loss for the full year 2025 was $44 million, down from $65.3 million in 2024 [24][25] Business Line Data and Key Metrics Changes - The small molecule biocatalysis business returned to a healthy profit margin in 2025, with stabilization in revenue expected to fuel growth for the next 3-5 years [9] - The ECO Synthesis platform achieved significant milestones, including synthesizing 10 grams of commercially relevant siRNA and scaling up production to 100 grams, with plans to reach half a kilo by the end of 2026 [5][6] Market Data and Key Metrics Changes - The total addressable annual market for production technologies in RNA medicine is estimated to be $2 billion in five years, with a growing demand for siRNA medicines at a rate of 5%-10% per year [4][5] - The industry is projected to require 10-30 metric tons of oligonucleotide material by 2030, indicating a significant addressable market for the company [55] Company Strategy and Development Direction - The company aims to establish itself as a key technology provider in the RNA medicine market, focusing on the ECO Synthesis platform to address production challenges [4][5] - Plans for 2026 include scaling up the ECO Synthesis manufacturing platform, achieving half-kilogram scale, and beginning construction of a GMP facility to support customer needs [7][28] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the demand for siRNA therapeutics and the company's ability to meet this demand through innovative technology [55] - The company anticipates that 2026 will be a year of significant progress, with a revenue target of $72 million to $76 million, and expects to maintain stable gross margins [25][27] Other Important Information - The company ended 2025 with $78.2 million in cash equivalents, expected to fund operations and capital expenditures through the end of 2027 [25] - A restructuring charge of $3.4 million was recorded in Q4 2025 as part of efforts to reduce operating costs and improve gross margins [24] Q&A Session Summary Question: Potential value for stereoisomer control - Management is actively exploring the biological activity of stereo configurations generated by the ECO Synthesis platform and plans to present data at the TIDES USA meeting [31][32] Question: Understanding the recent announced deal - The recent deal involves a small organization with a cardiovascular asset, and discussions have been ongoing for many months to address their manufacturing challenges [35][39] Question: Details on the 50-gram contract - The initial agreement is for preclinical work, and if successful, the company will progress to IND submissions and potentially commercial agreements for larger quantities [41][43] Question: Revenue guidance visibility - Management indicated that a significant portion of the $72 million-$76 million revenue guidance is based on historical buying practices, with some speculative elements due to the early part of the year [49][50] Question: Industry demand for siRNA - Management noted that the siRNA therapeutic pipeline is vibrant, with a growing number of assets in clinical trials, projecting a significant increase in demand by 2030 [53][55] Question: Revenue mix and growth expectations - The company expects growth to primarily come from the ECO side of the business, while the small molecule biocatalysis business is expected to stabilize and contribute to growth over the next few years [60][63]